Lewis DA
GLP-1 receptor signaling increases PCSK1 and cell features in human cells
So if this is not a pat, a patentable, like if it's not something you could put on patent, probably there are not gonna be a lot of, uh, pharma guys who are gonna really want to invest in it because you can't protect it
Research published on NIH/PMC documents that GHK-Cu at 1 to 10 nanomolar concentration stimulates both synthesis and breakdown of collagen and glycosaminoglycans, modulates metalloproteinase and TIMP activity as a main regulator of wound healing and skin remodeling, and has been confirmed to accelerate wound healing and increase blood vessel formation in animal models
Short-acting formulations reach peak plasma concentrations within 1-3.5 hours and have shorter elimination half-lives, while long-acting agents like semaglutide have half-lives of approximately one week, allowing for sustained therapeutic effects
How long should Semaglutide GLP-1 be used for weight management